Study: NCT06132217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simmitinib
Description: Patients will oral administration according to study protocol until disease progression, death, unacceptable toxicity, loss of follow-up, withdrawal of consent or other conditions meet the end of treatment criteria.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simmitinib
Description: Patients will oral administration according to study protocol until disease progression, death, unacceptable toxicity, loss of follow-up, withdrawal of consent or other conditions meet the end of treatment criteria.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simmitinib
Description: Patients will oral administration according to study protocol until disease progression, death, unacceptable toxicity, loss of follow-up, withdrawal of consent or other conditions meet the end of treatment criteria.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simmitinib
Description: Patients will oral administration according to study protocol until disease progression, death, unacceptable toxicity, loss of follow-up, withdrawal of consent or other conditions meet the end of treatment criteria.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simmitinib
Description: Patients will oral administration according to study protocol until disease progression, death, unacceptable toxicity, loss of follow-up, withdrawal of consent or other conditions meet the end of treatment criteria.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simmitinib
Description: Patients will oral administration according to study protocol until disease progression, death, unacceptable toxicity, loss of follow-up, withdrawal of consent or other conditions meet the end of treatment criteria.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SG001
Description: Patients will receive intravenous infusion of SG001 according to study protocol until disease progression, unacceptable toxicity, meeting the suspension or termination criteria, or up to 24 months in patients without disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SG001
Description: Patients will receive intravenous infusion of SG001 according to study protocol until disease progression, unacceptable toxicity, meeting the suspension or termination criteria, or up to 24 months in patients without disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SG001
Description: Patients will receive intravenous infusion of SG001 according to study protocol until disease progression, unacceptable toxicity, meeting the suspension or termination criteria, or up to 24 months in patients without disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SG001
Description: Patients will receive intravenous infusion of SG001 according to study protocol until disease progression, unacceptable toxicity, meeting the suspension or termination criteria, or up to 24 months in patients without disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SG001
Description: Patients will receive intravenous infusion of SG001 according to study protocol until disease progression, unacceptable toxicity, meeting the suspension or termination criteria, or up to 24 months in patients without disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SG001
Description: Patients will receive intravenous infusion of SG001 according to study protocol until disease progression, unacceptable toxicity, meeting the suspension or termination criteria, or up to 24 months in patients without disease progression.